Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA
Source: View publication →
In patients with mild-to-moderate acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack, a 30-day regimen of ticagrelor combined with aspirin reduced the risk of the composite of stroke or death compared to aspirin alone, albeit with an increased risk of severe bleeding.
Key Findings
Study Design
Study Limitations
Clinical Significance
The THALES trial provides evidence for a pharmacological strategy to reduce early recurrent stroke in high-risk patients. While dual antiplatelet therapy with ticagrelor and aspirin offers a reduction in ischemic events, the increased risk of severe bleeding requires clinicians to weigh the potential ischemic benefit against the heightened risk of intracranial hemorrhage on an individual patient basis.
Historical Context
Following the success of the CHANCE and POINT trials, which demonstrated that dual antiplatelet therapy (aspirin and clopidogrel) reduced early recurrence of ischemic events in minor stroke or high-risk TIA, THALES evaluated whether an alternative P2Y12 inhibitor, ticagrelor—which acts directly and is not dependent on cytochrome P450 activation—could provide similar or superior protection.
Guided Discussion
High-yield insights from every perspective
Ticagrelor and aspirin work through different pathways to inhibit platelet aggregation. What are their specific molecular targets, and why is dual antiplatelet therapy (DAPT) theoretically superior to monotherapy in the hyperacute phase of ischemic stroke?
Key Response
Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), preventing the synthesis of thromboxane A2, while ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist that inhibits ADP-induced platelet activation. Using both targets complementary pathways of platelet activation, which is crucial in the first 24-72 hours after a stroke when the plaque is most unstable and platelet reactivity is at its peak.
The THALES trial utilized a 30-day regimen of ticagrelor and aspirin. How does this duration and the inclusion criteria (NIHSS ≤ 5) compare to the POINT and CHANCE trials, and how does this affect your choice of DAPT for a patient with a high-risk TIA?
Key Response
CHANCE and POINT used clopidogrel-aspirin. CHANCE (China) treated for 21 days, while POINT (International) treated for 90 days. THALES showed that 30 days of ticagrelor-aspirin reduces stroke risk but increases severe bleeding (GUSTO criteria). Residents must balance the higher potency of ticagrelor against the increased bleeding risk compared to clopidogrel, especially in patients who may be clopidogrel 'non-responders' due to CYP2C19 polymorphisms.
In the THALES trial, the benefit of ticagrelor-aspirin was consistent across subgroups, but the risk of intracranial hemorrhage was notably higher in the DAPT group. How should the presence of underlying cerebral small vessel disease (e.g., high burden of microbleeds) influence your interpretation of the 'net clinical benefit' for a specific patient?
Key Response
While the primary composite outcome favored DAPT, the hazard ratio for severe bleeding was 3.99. Fellows must integrate neuroimaging markers: patients with high microbleed burdens or those on concurrent anticoagulation (excluded from THALES) are at significantly higher risk for hemorrhagic transformation or ICH, potentially negating the 1.1% absolute risk reduction in ischemic stroke seen in the trial.
The NNT to prevent one primary outcome event in THALES was 92, while the NNH for a severe bleeding event was 263. Given these numbers, how do you incorporate the THALES data into your institutional protocols for patients who present at the 12-hour mark, outside the traditional window for some previous DAPT protocols?
Key Response
THALES allowed enrollment up to 24 hours after symptom onset, broader than the 12-hour window in CHANCE. This provides a practice-changing evidence base for late-presenting minor strokes. Attendings should emphasize that while the NNT is favorable, the 'real-world' NNH may be lower in elderly populations with higher frailty than the trial participants, necessitating a personalized approach to the 30-day duration.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the use of the GUSTO bleeding criteria in THALES versus the BARC or TIMI scales. How might the choice of bleeding definition mask the 'nuisance' bleeding that leads to premature treatment discontinuation in a 30-day trial of a P2Y12 inhibitor?
Key Response
GUSTO criteria focus on 'severe' or 'life-threatening' events, which are rare but catastrophic. However, ticagrelor is known to cause higher rates of dyspnea and minor/moderate bleeding (which would be captured by BARC). If 'nuisance' bleeding leads to early cessation of therapy in the DAPT arm, the intention-to-treat analysis might underestimate both the true preventive efficacy and the true total bleeding burden of the drug.
The THALES trial reported a statistically significant reduction in stroke or death, but no significant difference in the secondary outcome of disability (mRS > 2). As a reviewer, how would you evaluate the clinical significance of preventing a 'minor recurrent stroke' if it does not result in a measurable shift in global functional outcomes at 30 days?
Key Response
Editors look for 'patient-important outcomes.' If the reduction in strokes (mostly minor) doesn't translate to better functional independence (mRS), the value proposition of a more expensive and higher-risk drug like ticagrelor is challenged. A tough reviewer would flag the discrepancy between the primary endpoint (event-based) and the functional endpoint (disability-based) as a limitation in the trial's impact on long-term quality of life.
Current AHA/ASA guidelines (2021) give a Class 2a recommendation for ticagrelor plus aspirin in minor stroke/high-risk TIA. What specific evidence from THALES justifies its place alongside the Class 1a recommendation for clopidogrel plus aspirin, and should the guidelines specify its use only in the absence of clopidogrel-related genetic or drug-drug interactions?
Key Response
The 1a recommendation for clopidogrel is based on multiple large trials (CHANCE/POINT). THALES provides a high-quality alternative (Level B-R), especially useful for the ~30% of the population with CYP2C19 loss-of-function alleles who do not metabolize clopidogrel effectively. The committee must decide if the increased bleeding risk of ticagrelor justifies it as a universal first-line option or if it should remain a secondary choice behind clopidogrel for most patients.
Clinical Landscape
Noteworthy Related Trials
CHANCE Trial
Tested
Clopidogrel plus aspirin
Population
Patients with high-risk TIA or minor ischemic stroke
Comparator
Aspirin alone
Endpoint
Stroke (ischemic or hemorrhagic) within 90 days
SOCRATES Trial
Tested
Ticagrelor monotherapy
Population
Patients with acute ischemic stroke or high-risk TIA
Comparator
Aspirin monotherapy
Endpoint
Time to first event of stroke, myocardial infarction, or death at 90 days
POINT Trial
Tested
Clopidogrel plus aspirin
Population
Patients with minor ischemic stroke or high-risk TIA
Comparator
Aspirin alone
Endpoint
Composite of ischemic stroke, myocardial infarction, or death from vascular causes at 90 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis